{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106606","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.362112+00:00","generated_at":"2026-06-10T04:34:05.174937+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Standard BioTools and SomaLogic to merge in all-stock deal valued over $1B","bullets":["SomaLogic shareholders get 1.11 LAB shares per SLGC share; combined ownership ~57% SLGC, ~43% LAB.","Estimated $80M annual cost synergies by 2026; pro-forma 2023 revenue >$180M.","Combined cash >$500M at close; LAB raises FY2023 revenue guidance to $100-105M.","Michael Egholm to become CEO of combined company; Jeffrey Black as CFO.","Standard BioTools and SomaLogic stockholders representing ~16% and ~1% voting power sign voting agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106606","json":"https://secwatch.observer/filing/0001104659-23-106606.json","markdown":"https://secwatch.observer/filing/0001104659-23-106606.md","text":"https://secwatch.observer/filing/0001104659-23-106606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000110465923106606/0001104659-23-106606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000110465923106606/tm2327474d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:34:05.174937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f8062ccdede0211087c19379131ff9cf889ddbb","claim":"STANDARD BIOTOOLS INC. entered into Agreement and Plan of Merger with SomaLogic, Inc. (effective 2023-10-04).","evidence_excerpt":"On October 4, 2023, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), SomaLogic, Inc., a Delaware corporation (“SomaLogic”), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000110465923106606/0001104659-23-106606-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"SomaLogic, Inc."},{"label":"Effective","value":"2023-10-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}